8-K: Xencor Announces Third Quarter 2024 Financial Results and Clinical Pipeline Updates

Xencor reported its third quarter 2024 financial results, highlighted by a $201.3 million public offering and progress in its clinical programs, including new autoimmune disease candidates.

Summary

• Xencor announced its financial results for the third quarter ended September 30, 2024, along with updates on its clinical programs.
• The company raised $201.3 million in gross proceeds through a public offering of common stock and pre-funded warrants.
• Xencor's cash, cash equivalents, and marketable debt securities totaled $754.3 million as of September 30, 2024, compared to $697.0 million at the end of 2023.
• Third-quarter revenues were $10.7 million, a decrease from $59.2 million in the same period of 2023, primarily due to a shift from milestone revenue to non-cash royalty revenue.
• Research and development expenses were $58.2 million for the quarter, down from $64.9 million in the same period last year.
• The net loss attributable to Xencor for the third quarter was $45.1 million, or $(0.71) per share, compared to a net loss of $24.3 million, or $(0.40) per share, in the same period of 2023.
• Xencor expects to end 2024 with between $690 million and $710 million in cash and believes it has sufficient funds to support operations into 2028.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While the company has a strong cash position and is making progress in its clinical programs, the significant decrease in revenue and increase in net loss are concerning. The successful capital raise and advancement of partnered programs are positive, but the overall sentiment is cautiously optimistic.

Positives

• The successful public offering raised significant capital, strengthening Xencor's financial position.
• Xencor is expanding its pipeline into autoimmune diseases with new drug candidates.
• Clinical programs are progressing, with several studies advancing to later stages.
• Partnered programs, such as Amgen's xaluritamig, are showing promising results and moving into Phase 3 development.
• Xencor has sufficient cash to fund operations into 2028.

Negatives

• Third-quarter revenues decreased significantly compared to the same period in 2023.
• The company reported a larger net loss for the third quarter of 2024 compared to 2023.
• Two patients experienced dose-limiting toxicities in the XmAb808 Phase 1 study, requiring a pause in dose escalation.

Risks

• Clinical trial outcomes are uncertain, and there is a risk that drug candidates may not be safe or effective.
• The company's financial performance is dependent on the success of its clinical programs and partnerships.
• There are risks associated with the process of discovering, developing, manufacturing and commercializing drugs.
• The company is subject to risks associated with publicly disclosed preliminary clinical trial data to support continued clinical development and regulatory approval for specific treatments.

Future Outlook

Xencor expects to end 2024 with between $690 million and $710 million in cash, cash equivalents and marketable debt securities, and to have cash to fund research and development programs and operations into 2028.

Management Comments

• Bassil Dahiyat, Ph.D., president and chief executive officer at Xencor, stated that the company has been rebalancing its portfolio to focus on programs that leverage its protein engineering strengths.
• Bassil Dahiyat also mentioned that they are highly encouraged by Amgen's progress with xaluritamig.

Industry Context

The announcement reflects the ongoing trend in the biopharmaceutical industry of developing novel antibody-based therapies for cancer and autoimmune diseases. Xencor's focus on bispecific antibodies and its partnerships with larger pharmaceutical companies like Amgen are consistent with industry trends.

Comparison to Industry Standards

• Xencor's cash position of $754.3 million is relatively strong compared to other clinical-stage biopharmaceutical companies, providing a runway into 2028.
• The decrease in revenue from $59.2 million to $10.7 million year-over-year is significant and may be concerning to investors, as it indicates a shift from milestone payments to lower non-cash royalty revenue.
• The increase in net loss from $24.3 million to $45.1 million year-over-year is also a negative trend, but is not uncommon for companies in the clinical stage of development.
• The advancement of xaluritamig into Phase 3 by Amgen is a positive sign for Xencor's technology and is comparable to other successful partnerships in the industry.
• The dose-limiting toxicities observed in the XmAb808 study are not uncommon in early-stage clinical trials and are being addressed by the company.

Stakeholder Impact

• Shareholders may be concerned about the decreased revenue and increased net loss, but encouraged by the strong cash position and clinical progress.
• Employees may be reassured by the company's financial stability and continued investment in research and development.
• Patients may benefit from the development of new therapies for cancer and autoimmune diseases.
• Partners like Amgen may be encouraged by the progress of partnered programs.

Next Steps

• Xencor plans to present initial data from the Phase 1 study of XmAb942 in the first half of 2025.
• Xencor plans to initiate a Phase 1b/2a study of plamotamab in rheumatoid arthritis in the first half of 2025.
• Xencor plans to provide clinical updates on XmAb808 and XmAb819 in the first half of 2025.
• Amgen will initiate a Phase 3 study of xaluritamig in the fourth quarter of 2024.

Key Dates

Keywords

Xencor, biopharmaceutical, engineered antibodies, clinical trials, oncology, autoimmune disease, T-cell engagers, XmAb, plamotamab, XmAb942, xaluritamig, financial results, public offering